

Supplementary Table 2: Summary of serious adverse events associated with the ICORG08-10 clinical trial and their associated impact on a patients treatment.

Summary of adverse events	N (%)
Number of subjects with serious adverse events	22 (20.8%)
# subjects who have chemotherapy treatment discontinued due to an adverse event	4 (3.8%)
# subjects who have bevacizumab treatment discontinued due to an adverse event	16 (15.1%)